Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQuartz Part B Step Therapy Prior Auth Update | Ope…
    Ask Trek AI about this page
    CurrentquartzPolicy N/A

    Part B Step Therapy Program Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all quartz policy alerts

    Know when quartz releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy prior authorization requirements for selected Part B drugs (medical benefit) and biosimilars for Quartz members; applies to providers requesting coverage for the listed HCPCS/J-codes and brand/generic products under the insurer's Part B program.

    Policy Summary
    Payerquartz
    PolicyPart B Step Therapy Program Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeMaterial additions and minor revisions
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateApr 21, 2026
    Key ActionProviders must document trials and failures (or contraindication/intolerance) of specified preferred drugs before coverage of non-preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    Add new denosumab step (Prolia, Xgeva, Ospomyv, Xbryk, Jubbonti, Wyost, Aukelso, Bosaya, Osenvelt, Stoboclo, Bomyntra, Conexxence, Osvyrti, Jubereq, Boncresa, Oziltus).

    Add Armlupeg.

    Remove bevacizumab.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsapproval limit for listed drugs
    Nonequantity limits for listed drugs
    Step therapyapplies to multiple non-preferred Part B products
    07/01/2026policy effective date

    Coverage Criteria

    Long-acting colony stimulating factors - Non-Preferred

    Covered when ALL of the following are met for non-preferred long-acting colony stimulating factors

    Long-acting CSF step: History of trial and failure, contraindication, or intolerance to TWO of the following preferred agents: Nyvepria, Fulphila, Udenyca, Udenyca Autoinjector, Udenyca On-body2 agents

    Required prior trials of two preferred long-acting CSFs

    Short-acting colony stimulating factors - Non-Preferred

    Covered when ALL of the following are met for non-preferred short-acting colony stimulating factors

    Short-acting CSF step: History of trial and failure, contraindication, or intolerance to TWO of the following preferred agents: Granix, Nivestym, Nypozi, Releuko, Zarxio2 agents

    Required prior trials of two preferred short-acting CSFs

    Denosumab - Non-Preferred

    Covered when ALL of the following are met for non-preferred denosumab products

    Denosumab step options: History of trial and failure, contraindication, or intolerance to either (1) Enoby and Bildyos, or (2) Xtrenbo and Bilprevdaeither pair

    Must demonstrate trial/failure of the specified preferred denosumab biosimilars/alternatives

    Epoetin alfa - Non-Preferred

    Covered when ALL of the following are met for non-preferred epoetin alfa products

    Epoetin step: History of trial and failure, contraindication, or intolerance to Retacrit1 agent

    Retacrit is preferred; trial required before Procrit/Epogen

    Hyaluronidase products - Non-Preferred

    Covered when ALL of the following are met for non-preferred hyaluronidase/viscosupplementation products

    Hyaluronidase step: History of trial and failure, contraindication, or intolerance to TWO of the following preferred agents: Euflexxa, Synvisc, Synvisc-One2 agents

    Required prior trials of two preferred viscosupplements

    Infliximab - Non-Preferred

    Covered when ALL of the following are met for non-preferred infliximab products

    Infliximab step: History of trial and failure, contraindication, or intolerance to TWO of the following preferred agents: Inflectra, Avsola2 agents

    Required prior trials of two preferred infliximab biosimilars

    Inclisiran (Leqvio) - Non-Preferred

    Covered when ALL of the following are met for non-preferred inclisiran

    Inclisiran step: History of trial and failure, contraindication, or intolerance to Repatha AND member is currently taking high-intensity OR a maximally tolerated statin OR has contraindication/intolerance to statin therapyRepatha plus statin context

    Statin requirement applies as stated

    Rituximab - Non-Preferred

    Covered when ALL of the following are met for non-preferred rituximab products

    Rituximab step: History of trial and failure, contraindication, or intolerance to TWO of the following preferred agents: Riabni, Ruxience, Truxima2 agents

    Required prior trials of two preferred rituximab biosimilars

    Trastuzumab - Non-Preferred

    Covered when ALL of the following are met for non-preferred trastuzumab products

    Trastuzumab step: History of trial and failure, contraindication, or intolerance to TWO of the following preferred agents: Kanjinti, Trazimera2 agents

    Required prior trials of two preferred trastuzumab biosimilars

    This policy follows applicable Medicare coverage guidance. Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and related manuals apply where relevant; providers should consult the Medicare Coverage Database for the most current Medicare policy. Where Medicare coverage differs from this policy, the applicable NCDs/LCDs take precedence.

    Coding and HCPCS/J-code Lists

    Denosumab-related HCPCS codesHCPCS
    J0897Denosumab (Prolia, Xgeva, Ospomyv, Xbryk, Jubbonti, Wyost, Aukelso, Bosaya, Osenvelt, Stoboclo, Bomyntra, Conexxence, Osvyrti, Jubereq, Boncresa, Oziltus)
    Q5136Denosumab - see listed brands
    Q5157Denosumab - see listed brands
    Q5158Denosumab - see listed brands
    Q5159Denosumab - see listed brands
    Q5161Denosumab - see listed brands
    Q5165Denosumab - see listed brands
    Q5166Denosumab - see listed brands
    Colony stimulating factors and relatedHCPCS
    J9361Efbemalenograstim alfa (Ryzneuta)
    J1449Eflapegrastim (Rolvedon)
    J0885Epoetin Alfa (Procrit, Epogen)
    J1442Filgrastim (Neupogen)
    Hyaluronidase / viscosupplement J-codesHCPCS
    J7318Hyaluronidase/viscosupplementation products
    J7320Hyaluronidase/viscosupplementation products
    J7321Hyaluronidase/viscosupplementation products
    J7326Hyaluronidase/viscosupplementation products
    J7328Hyaluronidase/viscosupplementation products
    J7322Hyaluronidase/viscosupplementation products
    J7327Hyaluronidase/viscosupplementation products
    J7324Hyaluronidase/viscosupplementation products
    J7331Hyaluronidase/viscosupplementation products
    J7332Hyaluronidase/viscosupplementation products
    Other Part B drugs and biosimilar codesHCPCS
    J1306Inclisiran (Leqvio)
    J1745Infliximab (Remicade, Renflexis, infliximab unbranded)
    Q5104Infliximab biosimilar
    J2506Pegfilgrastim (Neulasta and biosimilars)
    Q5120Pegfilgrastim biosimilar
    Q5127Pegfilgrastim biosimilar
    Q5130Pegfilgrastim biosimilar
    Q5169Rituximab (Rituxan)
    J9312Rituximab J-code
    Trastuzumab and biosimilarsHCPCS
    J9355Trastuzumab (Herceptin, Herzuma, Ogivri, Ontruzant, Hercessi)
    Q5146Trastuzumab biosimilar
    Q5114Trastuzumab biosimilar
    Q5113Trastuzumab biosimilar
    Continuation lookback — 365 days
    Lookback period365 days
    Applies toContinuation of prior therapy
    Source guidanceCRITERIA FOR CONTINUATION OF THERAPY: Continuation of prior therapy within the past 365 days.

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required; approvals limited to 12 months

    Prior authorization is required for the listed Part B J- and Q-codes; approvals are limited to 12 months per listed product unless otherwise noted.

    • Applies to the Part B HCPCS/J-codes listed in the policy (e.g., J0897, J9361, J1449, J0885, J1442, J7318, J1306, J1745, J2506, Q5169, J9355, etc.).
    • Approval limits: 12 months for listed products unless the policy specifies otherwise.
    Step Therapy

    Step therapy: document required trials/failures of preferred agents

    Providers must document trials and failures (or contraindication/intolerance) of the specified preferred drugs before coverage of non-preferred products; the required number of failed preferred agents varies by class (typically two agents or the specific pair noted for denosumab and inclisiran).

    • Most classes require history of trial and failure, contraindication, or intolerance to TWO preferred agents (e.g., long- and short-acting CSFs, hyaluronidase products, infliximab, rituximab, trastuzumab).

    Background

    This policy implements a Part B step therapy prior authorization program for medical-benefit drugs and biosimilars. Drugs are grouped by class with designated preferred and non-preferred products, and coverage of non-preferred agents requires documented trials of the specified preferred agents or documentation of contraindication or intolerance. Providers must supply evidence of prior trials and failures (or contraindication/intolerance) as described in the class-specific criteria, and continuation rules and Part D–specific notes apply where stated.

    Definitions

    Continuation therapy — Continuation of prior therapy
    DefinitionContinuation of prior therapy
    AllowanceContinuation of prior therapy within the past 365 days is allowed without meeting step therapy again
    DocumentationProvider must document evidence of continuation of prior therapy when requesting continuation

    Initial Therapy Criteria

    Initial therapy requirements

    Initial coverage requires trials of preferred agents

    Initial trial requirement: Documented trial and failure, contraindication, or intolerance to the specified preferred products for the applicable class before non-preferred product coverageas specified per class

    See class-specific step therapy details

    Continuation Therapy Criteria

    Continuation of therapy

    Continuation criteria

    Continuation of prior therapy within the past 365 days is allowed without meeting step therapy again365 days

    Applies to continuation of therapy

    Part D specific requirement

    Part D note

    Part D applicability: Requirement applies only to members who have Part D coverage with Quartz where notedN/A

    Policy includes Part D-specific requirement for inclisiran

    Step Therapy Details

    Drug class / non-preferred product(s)Required documented trial(s) of preferred agent(s)
    Long-acting colony stimulating factors — Non-preferred: Neulasta; Neulasta Onpro; Armlupeg; Fylnetra; Stimufend; Ziextenzo; Rolvedon; RyzneutaHistory of trial and failure, contraindication, or intolerance to TWO of: Nyvepria, Fulphila, Udenyca, Udenyca Autoinjector, Udenyca On-body
    Short-acting colony stimulating factors — Non-preferred: NeupogenHistory of trial and failure, contraindication, or intolerance to TWO of: Granix, Nivestym, Nypozi, Releuko, Zarxio
    Denosumab — Non-preferred: Prolia, Xgeva, Ospomyv, Xbryk, Jubbonti, Wyost, Aukelso, Bosaya, Osenvelt, Stoboclo, Bomyntra, Conexxence, Osvyrti, Jubereq, Boncresa, OziltusHistory of trial and failure, contraindication, or intolerance to either (1) Enoby and Bildyos, or (2) Xtrenbo and Bilprevda
    Epoetin alfa — Non-preferred: Procrit, EpogenHistory of trial and failure, contraindication, or intolerance to Retacrit
    Hyaluronidase / viscosupplementation products — Non-preferred: Durolane; Gel-One; Gelsyn-3; GenVisc 850; Hyalgan; Hymovis; Orthovisc; Monovisc; Supartz FX; Synojoynt; TriVisc; Triluron; Visco-3History of trial and failure, contraindication, or intolerance to TWO of: Euflexxa, Synvisc, Synvisc-One
    Infliximab — Non-preferred: Remicade, Renflexis, infliximab unbrandedHistory of trial and failure, contraindication, or intolerance to TWO of: Inflectra, Avsola
    Inclisiran (Leqvio) — Non-preferred: InclisiranHistory of trial and failure, contraindication, or intolerance to Repatha AND member is currently taking a high‑intensity OR maximally tolerated statin, or has statin contraindication/intolerance
    Rituximab — Non-preferred: RituxanHistory of trial and failure, contraindication, or intolerance to TWO of: Riabni, Ruxience, Truxima
    Trastuzumab — Non-preferred: Herceptin, Herzuma, Ogivri, Ontruzant, HercessiHistory of trial and failure, contraindication, or intolerance to TWO of: Kanjinti, Trazimera

    Quantity Limits

    Multiple listed Part B drugs — None
    Multiple listed Part B drugsNone
    Quantity limits statusQuantity Limits = None for listed Part B drugs
    Approval limitsApproval Limits = 12 months for listed products unless otherwise noted

    Biosimilar Guidance

    Billing Rule

    Try preferred rituximab biosimilars before Rituxan

    Before Rituxan (Rituximab) will be approved, the patient must have a history of trial and failure, contraindication, or intolerance to TWO of the preferred rituximab biosimilars Riabni, Ruxience, and Truxima.

    • Preferred agents to try: Riabni, Ruxience, Truxima
    • Required failures: two of the listed preferred biosimilars
    Billing Rule

    Try preferred infliximab biosimilars before Remicade/Infliximab

    Before coverage of Remicade, Renflexis, or unbranded infliximab, the patient must have a history of trial and failure, contraindication, or intolerance to TWO of the preferred infliximab biosimilars Inflectra and Avsola.

    • Preferred agents to try: Inflectra, Avsola
    Policy Summary
    Payerquartz
    PolicyPart B Step Therapy Program Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeMaterial additions and minor revisions
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateApr 21, 2026
    Key ActionProviders must document trials and failures (or contraindication/intolerance) of specified preferred drugs before coverage of non-preferred products.
    SourceLink
    On This Page
    Coverage CriteriaCoding and HCPCS/J-code ListsProvider Actions and RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy DetailsQuantity LimitsBiosimilar Guidance
  1. Denosumab requires trial/failure, contraindication, or intolerance to either (1) Enoby and Bildyos, or (2) Xtrenbo and Bilprevda (the specified pair).
  2. Inclisiran requires trial/failure or contraindication/intolerance to Repatha AND the member must be on (or intolerant/contraindicated to) high‑intensity or maximally tolerated statin therapy as specified.
  3. Documentation Required

    Required documentation: trials, failures, contraindications/intolerances, and continuation evidence

    Providers must document prior trials, failures, contraindications, or intolerances to the required preferred products and, when requesting continuation, evidence the member received the prior therapy within the past 365 days.

    • Document the specific preferred agents tried and the reason for failure, intolerance, or contraindication.
    • For continuation requests, provide documentation showing prior therapy within the last 365 days to qualify for continuation without re‑meeting step therapy.
    Denial Risk

    Denial risk if step therapy or Medicare coverage requirements are unmet

    Requests that do not meet the step therapy restrictions or applicable Medicare NCDs/LCDs may be denied.

    • Confirm applicability of Medicare NCDs/LCDs; where Medicare coverage differs, NCDs/LCDs apply and lack of compliance may result in denial.
  4. Required failures: two of the listed preferred biosimilars
  5. Billing Rule

    Try preferred trastuzumab biosimilars before Herceptin

    Before Herceptin or other non-preferred trastuzumab products are approved, the patient must have a history of trial and failure, contraindication, or intolerance to TWO of the preferred trastuzumab biosimilars Kanjinti and Trazimera.

    • Preferred agents to try: Kanjinti, Trazimera
    • Required failures: two of the listed preferred biosimilars